SCHEMBL6318554

SCHEMBL6318554

NC(=O)c1c(-c2ccncc2)noc1NC(=O)c1cc(F)cc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.47
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
AURKA O14965 1/20 0.37
TSHR P16473 1/20 0.37
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37
SRC P12931 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322937 0.90 CYP1A2 (0.48) MAPK14SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL6319348 0.89 MAPK14 (0.54) MAPK14CA1CA2CA4CA7
SCHEMBL6315543 0.85 TNIK (0.39) CA1CA2CA4CA7KMT2A
SCHEMBL6319728 0.84 TBK1 (0.52) MAPK14CA1CA2CA4CA7
SCHEMBL6319264 0.83 NPC1 (0.47) MAPK14KDRNPC1
SCHEMBL6321018 0.83 MAPK14 (0.47) MAPK14SMN1; SMN2MAPK1GAAALDH1A1
SCHEMBL6317602 0.82 KMT2A (0.51) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6318347 0.82 IKBKE (0.54) MAPK14SMN1; SMN2MAPK1KMT2AGAA
SCHEMBL6317864 0.81 ALDH1A1 (0.44) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL6316725 0.81 ABCB1 (0.53) SMN1; SMN2MAPK1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPK14 111/4885CA1 2406/4885CA2 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.